ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / MNKD / insiders
AVLN (44) AMPH (72) VSTM (36) JANX (37) ⌘ Pro Terminal →

MannKind Corporation (MNKD) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$3.65 +4.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.67

MannKind Corporation (MNKD) carries a Roarable Rating of D+ (Sell) with 56/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D+ • SELL / AVOID Cap $1.13B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on MNKD Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is MNKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, MannKind Corporation (NASDAQ: MNKD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $3.65 (+4.29% 1D, market cap $1.13B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, MNKD ranks #199 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does MNKD compare to AVLN and AMPH in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNKD carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 92.3%, and ROIC of 54.5%. By comparison, AVLN (Avalyn Pharma Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.14B) and AMPH (Amphastar Pharmaceuticals Inc.) posts a B grade (72/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.18B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while MNKD leads on capital efficiency (54.5% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for MNKD?
▼

Per MNKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000899460), MannKind Corporation generated $349.0M in revenue (+22.2% YoY), $5.9M in net income, and $13.7M in free cash flow against $792.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $3.67 (+0.58%)🧬 Disciplined Float (-0.32% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 3.9% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 56/100 (D+) historically posted market-perform odds over rolling 90-day windows (-0.4% avg 90D alpha vs SPY • 51.8% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D+
025507510056
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C- · Rk D
Cash (14)Whales (9)SEC (12)Macro (8)CEO (13)
Each axis scored 0–20
12M PRICE TARGET CONE-0.8% Base Target
$7 Bull$4 Base$3 Bear
📬 FREE MNKD RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MNKD)Realized 20D OHLCV Swing Band: ±10.4%
Deterministic 5-Pillar Attribution (56/100 Composite)
🔍 WHY MNKD SCORES 56/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+14/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 3.9% FCF Margin ($13.7M FCF) & 92.3% Gross Margin

▲ #2 Bullish Driver: Insider Conviction & Share Dilution+13/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 65% Net Buy • Disciplined Float (-0.32% YoY Shares)

▼ #1 Drag / Risk Factor: Macro Regime Fit8/20 pts (-12 pt drag)

Macro rate sensitivity & RSI-14 (55.6) create a -12 pt regime headwind

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
48
Grade D$3.05+1.6% Next Q
Q2 (-2Q)
51
Grade C-$3.10+6.1% Next Q
Q3 (-1Q)
53
Grade C-$3.29+10.9% Next Q
Current
56
Grade D+$3.65-0.4% Hist 90D α
Trajectory: D (48) → D+ (56)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the MNKD Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 56/100 (D+) score, MNKD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Sensitive to high interest rates and tighter Federal Reserve market liquidity.

⚠️ Forensic Kill-Switch #2

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($3.56) or 200D SMA ($3.71) invalidates the momentum regime and cuts Target Base ($3.62) toward Bear Floor ($2.82).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $MNKD• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MNKD Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 56%NO 44%Trade / Inspect Odds →
SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

MNKD Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales →
▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (MNKD)

No recent open-market Form 4 cluster sales or emergency dumps flagged on MNKD. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MNKD)

  • ✓Walkthrough of MNKD's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
MNKD // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +29.89%▼ DESCENDING CHANNEL
2026-11-03O $3.50H $3.65L $3.50C $3.65VOL 2.01M
RES: $4.20SUP: $2.70SMA50: $3.56SMA200: $3.71
$4.74$4.19$3.65$3.10$2.55RES $4.20SUP $2.70$3.652026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

MNKD Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 MNKD Butterfly Map → + Track MNKD →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
23.7%/yr Implied 5Y Growth

vs. +22.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on MNKD today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for MNKD. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MNKD today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MNKD)

Health Care Rank #199 of 1015 ⚔️ AVLN vs MNKD Full Matrix →

1. Head-to-Head Health Care Peer Comparison (MNKD vs. AVLN, AMPH, VSTM, JANX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, MannKind Corporation (MNKD) ranks #199 by composite RQD confidence (56/100, grade D+) and #341 by equity capitalization ($1.13B). Within this direct 5-issuer industry benchmark cohort, AMPH leads on earnings valuation at 11.7x trailing P/E, while MNKD leads on capital efficiency and profitability with 54.5% ROIC and 92.3% gross margin. AMPH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with MNKD at 56/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
MNKD ACTIVE
MannKind Corporation
D+ 56/100 — 92.3% 54.5% +4.29% $1.13B Benchmark Subject
AVLN
Avalyn Pharma Inc.
D 44/100 — — — -0.12% $1.14B /avln-vs-mnkd →
AMPH
Amphastar Pharmaceuticals Inc.
B 72/100 11.7x 49.5% 9.0% -2.49% $1.18B /amph-vs-mnkd →
VSTM
Verastem Inc.
D- 36/100 — — -35.0% -1.64% $1.18B /vstm-vs-mnkd →
JANX
Janux Therapeutics Inc.
D- 37/100 — — -13.8% -0.06% $1.07B /janx-vs-mnkd →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000899460 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), MannKind Corporation (MNKD) reported GAAP revenue of $349.0M (+22.2% vs. FY2024 revenue of $285.5M , and +75.4% cumulative change since FY2023) , GAAP net income of $5.9M, operating cash flow of $18.3M, and free cash flow of $13.7M (-58.3% YoY). On the balance sheet, MNKD closed FY2025 with $792.2M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $349.0M $5.9M $18.3M $13.7M $792.2M —
FY2024 (FY) 2024-12-31 $285.5M $27.6M $42.5M $32.8M $393.8M —
FY2023 (FY) 2023-12-31 $199.0M -$11.9M $34.1M $34.1M — —

3. MNKD Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is MNKD stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, MannKind Corporation (NASDAQ: MNKD) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 56/100 at a spot price of $3.65 (+4.29% 1D, market cap $1.13B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, SEC Balance-Sheet Forensics 12/20, FRED Macro Regime Fit 8/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, MNKD ranks #199 in composite RQD confidence.

How does MNKD compare to AVLN and AMPH in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), MNKD carries a Roarable D+ (56/100 RQD), trailing P/E of N/A, gross margin of 92.3%, and ROIC of 54.5%. By comparison, AVLN (Avalyn Pharma Inc.) holds a D grade (44/100 RQD, P/E N/A, ROIC —, cap $1.14B) and AMPH (Amphastar Pharmaceuticals Inc.) posts a B grade (72/100 RQD, P/E 11.7x, ROIC 9.0%, cap $1.18B). Among the 5-stock peer group, AMPH leads on earnings multiple (11.7x) while MNKD leads on capital efficiency (54.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for MNKD?

Per MNKD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000899460), MannKind Corporation generated $349.0M in revenue (+22.2% YoY), $5.9M in net income, and $13.7M in free cash flow against $792.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.

Where is MNKD trading relative to its 50-day, 200-day, and 52-week technical levels?

MNKD last traded at $3.65 (+4.29% on volume of 3,175,147 shares), positioning the stock +2.53% above its 50-day simple moving average ($3.56) and -1.62% below its 200-day simple moving average ($3.71). Across its 52-week range of $2.23 to $6.51, MNKD sits at the 33.2% percentile with a 14-day RSI of 55.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±10.4% ($3.27 to $4.03).

Direct Sub-Reports: MNKD RQD Cockpit MNKD 12M Forecast MNKD Earnings & Move MNKD Dividends & DRIP MNKD Insiders & 13F MNKD Whale Options MNKD Profit Sankey MNKD News & Why
ROARABLE RATING BRIEF • RQD 56/100 (D+) ✓ SEC XBRL & RQD VERIFIED

MNKD — MannKind Corporation: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

MannKind Corporation (MNKD) earns a live Roarable RQD composite score of 56/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $3.65 (+4.29% 1D, market capitalization $1.13B).

  • Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 54.5%, gross margin of 92.3%, operating margin of 11.1%, and free cash flow yield of 1.22%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (13/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (8/20) + Forensic Balance Sheet (12/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 7/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

MannKind Corporation (MNKD) is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry..1B. Reported revenue for FY 2025 was $349.0M.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), MannKind Corporation (MNKD) reported $349.0M in annual revenue (up from $285.5M in FY2024, +22.2% YoY) and $5.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($199.0M revenue, -$11.9M net income) through FY2025, MNKD scaled operating cash flow to $18.3M and free cash flow to $13.7M, backed by $792.2M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D+ • RQD 56/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of 1.22% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $2.23 – $6.51 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Investors must weigh current valuation and 24.6x EV/EBITDA against 11.1% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), MNKD carries a macro regime beta of 1.00 and gross margin of 92.3%.

  • Key Question #1: Can MNKD sustain or expand its 11.1% operating margin and 54.5% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $349.0M and free cash flow of $13.7M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is MNKD's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

MNKD Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for MannKind Corporation (MNKD) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to MNKD Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

MNKD Bull vs. Bear Conversation Board — What's Your Call at $3.65?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MNKD 🐻 33% BEARISH CONVICTION
1. Pick Your Side on MNKD:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $4.38 (+25.1%)
📌 Pinned Debate

ROIC of 54.5% and cash rising from $46.3M to $74.9M indicate the operating engine is generating returns on capital despite a weak overa

Don't sleep on MNKD's setup in Health Care. ROIC of 54.5% and cash rising from $46.3M to $74.9M indicate the operating engine is generating returns on capital despite a weak overall rating.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (56/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@MidwestValue Agree on the RQD 56/100 quality, though with 1.0 beta I'm scaling in with half-size at $3.50 and keeping dry powder in case we test $3.26.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $2.77 (-20.9%)
Spot @ $3.50

An Altman Z-Score of 0.2 combined with net income falling to $5.9M in FY 2025 signals financial distress risk alongside a 1.22% FCF yie

Here is the bear case nobody on the bull side wants to address on MNKD: An Altman Z-Score of 0.2 combined with net income falling to $5.9M in FY 2025 signals financial distress risk alongside a 1.22% FCF yield.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%